Q4 2024 Geron Corp Earnings Call Transcript

Feb 26, 2025 / 01:00PM GMT

Release Date Price: €1.57 (-30.28%)

Transcript 10-K8-K

Key Points

Positve

Geron Corp (GERN) achieved FDA approval for Rytelo in June 2024, marking a significant milestone for the company.
Rytelo received favorable placement in the MDS NCCN guidelines, including a Category 1 treatment recommendation.
The company reported $47.5 million in Rytelo net product revenue in Q4 2024, exceeding internal expectations.
Geron Corp (GERN) ended the year with a strong cash position of approximately $503 million, which is expected to support profitability without additional financing.
The Phase III IMpactMF trial for imetelstat in myelofibrosis is 80% enrolled, with potential to transform treatment for relapsed/refractory myelofibrosis patients.

Negative

Despite initial success, Geron Corp (GERN) observed flat revenue trends for Rytelo over the last few months.
The majority of new patient starts for Rytelo have been in the third-line plus segment, with lower than expected starts in the second line.
There is variability in regional and account-level performance, indicating inconsistent uptake across different territories.
The company had to change its commercial and medical affairs leadership a few months into the Rytelo launch, indicating potential initial missteps.
Geron Corp (GERN) has not provided specific revenue guidance for 2025, citing the need for more quarters of data to establish reliable forecasts.

Operator

Hello, and welcome to the Geron first-quarter and full year 2024 earnings call. (Operator instructions).

I would now like to turn the conference over to Aron Feingold, Vice President of Investor Relations and Corporate Communications. You may begin.

Aron Feingold

Geron Corp - Vice President, Investor Relation and Corporate Communication

Good morning, everyone. Welcome to the Geron Corporation fourth-quarter and full year 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communications.

I'm joined today by several members of Geron's management team, Dr. John Scarlett, Chairman and Chief Executive Officer; Michelle Robertson, Executive Vice President and Chief Financial Officer; Jim Ziegler, Executive Vice President and Chief Commercial Officer; Dr. Joseph Eid, Executive Vice President, Research and Development; and Dr. Faye Feller, Executive Vice President and Chief Medical Officer.

Before we begin, please note that during the course of this presentation and question and

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.